SuMMaRy: as CER data proliferate, questions are being raised about who can access the data, who can discuss it, and in what forums. Regulations place different communication restrictions on the pharmaceutical industry than on other health care stakeholders, which creates a potential inequality. another CER consideration will be the tendency to apply average results to individuals, even if not every individual experiences the average result. Policy makers should implement CER findings carefully with a goal toward accommodating flexibility. a final impact to consider is whether greater expectations for CER will have a negative or positive effect on incentives for drug innovation. In some cases, CER may increase development costs or decrease market size. In other cases, better targeting of trial populations could result in lower development costs.
ConCLuSIon: the rising expectations and growth in CER raise questions about information access, communication restrictions, flexible implementation policies, and incentives for innovation. Members of the pharmaceutical industry should be cognizant of the questions and should be participating in dialogues now to pave the way for future solutions. • The amount of and demand for comparative effectiveness research (CER) is increasing.
• Regulations place different communication restrictions on the pharmaceutical industry than on other health care stakeholders. • CER will affect policy makers' decision making and drug manufacturers' development costs.
What is already known about this subject
• This article invites dialogue about the communication restrictions between the pharmaceutical industry and other health care stakeholders, with an eye toward affecting future regulations in a positive way.
• As policy makers expand their use of CER data, they should be cautious in applying average results to subgroups or individual patients. • CER's effects on future innovation may be both negative (e.g., increased trial sample sizes, longer-term endpoints, or the risk of unfavorable results) and positive (e.g., reduced sample sizes by identifying target subgroups earlier in development, or real-world data that show increased value for the drug, spurring further development). Therefore, regulators and developers must begin exploring ways to prepare for potential impacts.
What this article adds
What are the solutions? Should the communication restrictions on the pharmaceutical industry be loosened when their products are studied by others? Should there be a uniform set of communication standards that apply to all? There are no clear answers, but conversations about them should begin.
Applying Average Outcomes to Individual Patients
Every day, peer-reviewed publications or communication from the National Institutes of Health or the Agency for Healthcare Research and Quality detail the latest results of new clinical studies or systematic reviews. In the future, it will be overwhelming to try to keep up with the new data from the hundreds of studies that will be generated every year. To simplify information overload, the inclination is to remember the bottom line-is A better than B? Although we know logically that individual patients respond differently, we may focus upon the average result. But the reality, of course, is that the average is a composite and may not apply to each individual. As Kravitz et al. (2004) point out, heterogeneity of treatment has many meanings. 6 Inter-study heterogeneity entails comparison of results among several studies. Did those separate studies lead to very similar or very different results? Perhaps the population differed in each study and accounts for the different results. A second type of heterogeneity (inter-patient) relates to typical comparisons of A versus B where the data show that some patients did well and others did not. Rose's 1985 epidemiology paper is a well-known source on this topic. 7 The issue of heterogeneity of treatment has current relevance as the draft of the Essential Health Benefits (a component of the PPACA) requires that only a single agent be available in each drug class. 4 Perhaps the most clinical-or policy-relevant type of heterogeneity relates to how patients' individual responses may differ from the study average.
Let's examine a hypothetical example where patients on average do better on the "blue pill" than on the "red pill," an example similar to one recently used by President Obama in a national broadcast. 8 But individual patients may do better on the red pill than the blue pill for many reasons, including biologic or demographic distinctions or patient preferences. Policy makers reading an article about a study may note that the average result shows blue is better than red, and develop policies stating that everyone with a particular condition should receive the blue pill. The problem, of course, is that developing such a policy does not account for those individuals for whom the red pill works better. How can decision makers in managed care and PBMs work around this problem?
One commonly discussed theme is subgroup analysis. For example, in this same hypothetical study, we may discover that younger people respond differently than older people. We could falsely assume that the heterogeneity is now resolved and recommend that all younger people receive the blue pill, and all older people receive the red pill. 9 Unfortunately, the provided funding to invest in the development of various sources of information. For example, the FDA will have databases from which it will be mining and releasing information. Medicare will be making some of its data available for comparative purposes. Various other public and private databases will be used for CER. All of these information repositories will allow more and more researchers-from manufacturers, academics, the government, health plans, and others-to compare the performance of drugs to each other and to other therapies in ways that previously have not been feasible. With researchers and others looking at available data, questions arise as to who has the right to access this information, and who has the right to talk about what is found. Historically, it has been very difficult and expensive to access data, and those data were often limited in the populations they contained. But, as more data opportunities become available, there needs to be an open debate about the pros and cons of having this information widely available. The more people who have access to the data and can work with it, the more this issue has relevance. Multiple researchers will be able to analyze the same data and openly discuss different results, methods, or endpoints. Will pharmacy benefit management (PBM) companies or health plans consider supporting these open databases and sharing their own information? Will all parties have similar access rights, or will just selected government personnel or a handful of researchers have that access? Or will access to taxpayer-funded data be generally available? There may be no right answer, but the conversation should begin.
Another aspect of communication relates to who can communicate CER findings. Currently, the pharmaceutical industry can speak to physicians and pharmacists about their drugs as long as the conversation addresses using the drug for on-label indications. They can describe the indications and the endpoints that were part of registrational trials. Off-label communication is far more restricted even though off-label use occurs quite commonly, especially in oncology. 5 Other organizations or agencies do not have these restrictions. Moreover, when these groups conduct a study and publish the results, should the pharmaceutical companies that created the drugs be allowed to comment on the studies, whether to agree or suggest alterations or provide additional data? Currently, rules place far greater communication restrictions on the pharmaceutical industry than on anyone else in health care. This limits the pharmaceutical industry from responding with relevant information to the public debate. Today, pharmaceutical companies need multiple clinical trials to support assertions, but all other organizations-payers, the government, and the FDA-can make comparisons without conducting multiple trials or obtaining approval prior to dissemination. In other words, the dialogue becomes unequally restrictive, potentially to the detriment of the patients we aim to serve.
As CER increases the pool of information to discuss, the restrictions in place today become increasingly problematic. development costs may fall.
Another potential consequence is that certain drugs may not be pursued for clinical development. If a drug comes to market for indication A, but its clinical effectiveness is not shown to greatly differ from the alternative, payers may decide not to reimburse it or to place this new drug in a higher tier. If that happens, the manufacturer may not continue drug development-and risk-of testing it for indication B, where the drug might have performed better than any other drug available. And if a drug never makes it to the market, its descendent, derivative drugs will not be discovered. This is an important issue as a premium price cannot be obtained for a truly innovative product if the incremental steps to its development are not met. However the payer is not willing to pay for incremental developments. If this is the case then these costs get absorbed into the overall development of the innovative product, as recently described by Mansley, et al.
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On the other hand, CER could have a positive effect on innovation. For example, a manufacturer may identify a patient subgroup with biologic or genetic tests, perhaps, before starting clinical trials. In that case, the trials may show clear-cut success, and the clinical trial could be small, keeping costs low. In addition, as a manufacturer develops CER spanning multiple outcomes, including long-term real-world data, productivity improvement, and quality of life, perhaps the research will find even more value.
The increasing expectations of CER present many challenges. Patients and other health care decision makers want this information, and it is correct and beneficial to ask for it. However, it is important to recognize that there are consequences that may affect the viability of bringing drugs to market in both negative and positive ways. As Berger and Grainger (2010) point out, it is clear that there will be ongoing debate on how the pharmaceutical industry should incorporate CER into drug development. 12 Organizations will need to consider how they will balance the impact of CER's impact on innovation against the benefits of CER evidence.
The National Pharmaceutical Council has begun modeling projects to evaluate some of the impacts CER may have on the future of the pharmaceutical industry, but it is too soon to share data or make any predictions. It is not too soon, however, to consider the questions and begin the necessary dialogue toward solutions. And it is likely that there will be solutions, because the value of CER is not, in this author's opinion, in question. It is how to manage the impacts of CER that requires our attention. One possible example might be to offer different durations of patent life depending on whether a manufacturer conducts placebo trials or the longer and more expensive (and more desirable) comparative trials.
■■ Conclusions
It is important for the pharmaceutical industry to participate in the dialogue on the way CER is conducted, interpreted, and implemented. Many other countries are further along than the reality is that subgroups will not fully solve the problem, because there will still be heterogeneity even within these subgroups. In other words, not all of the older people will do better on the red pill. Using subgroups may be a step in the right direction, but it is not a complete solution.
CER data should affect population reimbursement policies, but when is that safe and when is it problematic? If patients have a chronic, slowly deteriorating or nondeteriorating illness (such as hay fever or fibromyalgia), they can safely initiate treatment with the blue pill, and if that does not work, they can try the red pill next. On the other hand, if they have a severe infection or cancer that is rapidly progressive, they do not have the luxury of trying one option and then switching to another. As policymakers integrate the red and blue pills into their reimbursement approaches, they must keep in mind that in some circumstances it will be fine to institute policies where everyone first should receive the blue pill, or the blue pill merits a lower copayment or a different tier, and then anyone who fails on the blue pill can move on to the red pill. But in other circumstances where perhaps the situation is clinically different, the risks are different, the deterioration possibility is different, or the way the curves overlap is different, then having a strict, centralized policy may be the wrong solution. In those circumstances, it might be better to grant more freedom to the doctor and patient, creating a decentralized decisionmaking policy.
Patient cost-sharing should also consider treatment heterogeneity. If someone is biologically different and he has tried the blue pill because that is the policy, but he does not respond to it and therefore has to try the red pill, why is his cost-sharing higher? It may be a nonpreferred drug, but biologically he failed the preferred drug. If he is biologically different, should he be penalized by having to pay more?
Integrating CER into decision making will bring these questions to the forefront. With comparative data, policy decisions should not be treated as one-size-fits-all. Sometimes centralized reimbursement approaches make sense. It is cost-effective, it is the right thing to do, and it will not harm patients. But other clinical circumstances may call for more flexible policies that allow the doctor and patient more ability to choose.
How Will the Growth of CER Impact Innovation?
The growing demand for CER will impact the pharmaceutical industry in many ways, and its effect on innovation may be difficult to predict. In a CER environment, the costs of drug development may rise. For example, if the marketplace requires active comparators instead of placebo, the sample size required to show statistical differences will increase. A larger sample size entails greater cost. 10 Second, demands for long-term clinical rather than short-term surrogate endpoints will increase study duration and attendant costs. Third, CER entails exploration of response in patient subgroups. To achieve adequate power, sample sizes will need to be larger. If particular subgroups show greatest benefit and lesser harm, then patients gain from this new knowledge, but the market size and revenue to offset United States in the application of CER to health technology decisions, and the pharmaceutical industry can benefit from internal discussions across global sectors in how this is done, especially since multinational corporations already are dealing with CER in its various forms in other parts of the world. 13 There should be broad access to taxpayer-funded data by all stakeholders, and the public and pharmaceutical industry should have the right to talk about whatever CER studies are performed. We all need to explore when average results may or may not be applied to individual patients. An early and active public dialogue will benefit all stakeholders.
